Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation

Trial Profile

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Lasofoxifene (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Sermonix Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2018 Status changed from planning to not yet recruiting.
    • 10 Dec 2018 According to a Sermonix Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) accepted the companys Investigational New Drug (IND) application and the study is expected to begin enrollment in early 2019.
    • 17 Nov 2017 According to the Ligand Pharmaceuticals media release, company expects to star the trial in Q4 2018, with topline data in 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top